Wengrower D, Fich A, Goldin E, Eliakim R, Ligumsky M, Rachmilewitz D
Dig Dis Sci. 1987 Aug;32(8):857-60. doi: 10.1007/BF01296709.
The efficacy of arbacet (a synthetic analog of prostaglandin E2) in definite cytoprotective but minimal antisecretory dose was evaluated in the treatment of duodenal ulcer. One hundred five patients with endoscopically proven duodenal ulcer were randomized in a double-blind manner to receive four times daily either arbacet 25 micrograms or placebo. Ulcer healing was assessed endoscopically after two and four weeks of treatment. The mean age, sex distribution, and tobacco and alcohol consumption were similar in the two treatment groups. The ulcers of 16 patients in both the placebo and the arbacet-treated group healed after 14 days of treatment. At the end of the study, healing of the ulcer was observed in 69.2% of the arbacet-treated patients and in 60.4% of patients in the placebo treated group. (Difference was not statistically significant). We conclude that cytoprotective doses of arbacet with minimal antisecretory properties are not effective in duodenal ulcer healing.
在十二指肠溃疡治疗中,评估了arbacet(一种前列腺素E2的合成类似物)在确定的具有细胞保护作用但抗分泌作用极小剂量下的疗效。105例经内镜证实为十二指肠溃疡的患者被双盲随机分组,每天四次接受25微克arbacet或安慰剂治疗。治疗两周和四周后通过内镜评估溃疡愈合情况。两个治疗组的平均年龄、性别分布以及烟草和酒精消费量相似。安慰剂组和arbacet治疗组中各有16例患者的溃疡在治疗14天后愈合。研究结束时,arbacet治疗组69.2%的患者溃疡愈合,安慰剂治疗组60.4%的患者溃疡愈合。(差异无统计学意义)。我们得出结论,具有极小抗分泌特性的细胞保护剂量的arbacet对十二指肠溃疡愈合无效。